-
Article
Open AccessThonzonium bromide inhibits progression of malignant pleural mesothelioma through regulation of ERK1/2 and p38 pathways and mitochondrial uncoupling
Malignant Pleural Mesothelioma (MPM) is a rare malignancy with a poor prognosis. Current therapies are unsatisfactory and novel cures are urgently needed. In a previous drug screening, we identified thonzonium...
-
Article
Open AccessAntitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo
Malignant mesothelioma (MM) is a rare tumor with a dismal prognosis. The low efficacy of current treatment options highlights the urge to identify more effective therapies aimed at improving MM patients’ survi...
-
Article
Open AccessThe role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
Non-small cell lung cancer (NSCLC) is frequently complicated by central nervous system (CNS) metastases affecting patients’ life expectancy and quality. At the present clinical trials including neurosurgery, r...
-
Article
Open AccessThe function and clinical implication of YTHDF1 in the human system development and cancer
YTHDF1 is a well-characterized m6A reader protein that is essential for protein translation, stem cell self-renewal, and embryonic development. YTHDF1 regulates target gene expression by diverse molecular mech...
-
Article
Open AccessAnalysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
In this commentary, using existing clinical trial data and FDA approvals we propose that there is currently a critical need for an appropriate balancing between the financial impact of new cancer drugs and the...
-
Article
Open AccessCorrection: P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
Author Francesca Pentimalli was incorrectly associated with Histopathological Unit, IRCCS-Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy. The author’s actual affiliation is Cell...
-
Article
Open AccessP53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive cancer, related to asbestos exposure, which has a dismal prognosis. MPM diagnosis is late and often challenging, suggesting the need to identify more relia...
-
Article
Open AccessTissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report)
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm of the pleura, mainly related to asbestos exposure. As in other solid tumors, malignant cells exhibit high glucose uptake and glycolytic rates wit...
-
Article
Open Accessp53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification
Malignant pleural mesothelioma (MPM) is an orphan disease that is difficult to treat using traditional chemotherapy, an approach which has been effective in other types of cancer. Most chemotherapeutics cause ...
-
Article
Open AccessDeregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism
Malignant pleural mesothelioma (MPM) is an aggressive human cancer and miRNAs can play a key role for this disease. In order to broaden the knowledge in this field, the miRNA expression was investigated in a l...
-
Article
Open AccessThe inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells
Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after cytotoxic drug treatment ...
-
Article
Open AccessIn vitro and in vivo characterization of highly purified Human Mesothelioma derived cells
Malignant pleural mesothelioma is a rare disease known to be resistant to conventional therapies. A better understanding of mesothelioma biology may provide the rationale for new therapeutic strategies. In thi...
-
Article
The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma
Ribonucleases are a superfamily of RNA-cleaving enzymes that can be cytotoxic since the cleavage of RNA makes its information indecipherable. Ranpirnase is a novel ribonuclease which preferentially degrades tR...
-
Article
Advances in the systemic therapy of malignant pleural mesothelioma
Major advances in the first-line therapy of inoperable malignant pleural mesothelioma have occurred in the past 5 years. This Review summarizes evidence supporting the clinical activity of chemotherapy, discus...
-
Article
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
-
Article
Malignant Mesothelioma as both a challenge and an opportunity
The International Mesothelioma Interest Group sponsored its 7th international meeting in Brescia, Italy from June 24–26, 2004. The meeting, entitled ‘How advanced technology and new drugs are changing the pers...
